Paxalisib, Kazia's lead program is now in a pivotal study for registration that puts us in a fairly rarified group of Phase III companies worldwide. A very exciting position to be in.
Kazia is well funded, money in the Bank. For a pre-revenue biotech company this is always an incredible point of focus for the ability to fund our programs.
Uniquely diversified across 7 different clinical trials mitigating risk and magnifying commercial opportunity.
One of the most exciting and very, very rich portfolios of clinical trial work that James has worked on in his 20 years in drug development experience. If we "win" one of these studies to be successful. If we "win" two, then we are absolutely off to the races and If we "win" more than that, then the sky is really the limit.
Incredible level of clinician interest that we have in the Paxalisib program.
KAZIA IS AN EXTREMELY ATTRACTIVE OPPORTUNITY FOR PARTNERING.
KZA Price at posting:
87.5¢ Sentiment: Buy Disclosure: Held
